Breast cancer risk is similar for CHEK2 founder and non-founder mutation carriers  by Leedom, Tracey P. et al.
Breast cancer risk is similar for CHEK2 founder and
non-founder mutation carriers
Tracey P. Leedom a,*, Holly LaDuca a, Rachel McFarland a, Shuwei Li a,
Jill S. Dolinsky a, Elizabeth C. Chao a,b
a Department of Clinical Diagnostics, Ambry Genetics, 15 Argonaut, Aliso Viejo, CA 92656, USA; b Department of Pediatrics,
Division of Genetics and Genomic Medicine, University of California, 2054 E. Hewitt Hall, Irvine, CA 92697, USA
CHEK2 mutations are associated with increased cancer risks, including breast; however, pub-
lished risk estimates are limited to those conferred by CHEK2 founder mutations, presenting
uncertainty in risk assessment for carriers of other CHEK2 mutations. This study aimed to assess
phenotypes and molecular characteristics of CHEK2 mutation carriers (CHEK2 + s) from a multi-
gene panel testing (MGPT) cohort, focusing on comparing phenotypes of founder and non-
founder CHEK2 + s. Clinical histories and molecular results were reviewed from 45,879 patients
who underwent MGPT including CHEK2 at a commercial laboratory. Of individuals tested, 2.4%
(n = 1085) were CHEK2 + s. Sixteen individuals harbored biallelic CHEK2 mutations, bringing the
total number of CHEK2 mutations detected in this cohort to 1101. Personal/family cancer histo-
ries were compared between founder (n = 576; included c.1100delC, p.S428F, c.444 + 1G > A,
and EX8_9del) and non-founder (n = 259) CHEK2 + s using Fisher’s exact test and multivariate
logistic regression analysis. Individuals carrying the p.I157T moderate risk founder mutation (n = 231),
additional mutations in non-CHEK2 genes (n = 83), or biallelic mutations (n = 16) were excluded
from phenotype analysis, as were cases with no clinical information provided. No significant phe-
notypic differences were observed between founder and non-founder CHEK2 + s. These data suggest
that cancer risks reported for founder mutations may be generalizable to all CHEK2 + s, partic-
ularly for breast cancer.
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Introduction
Mutations in the CHEK2 gene are associated with increased
risks of developing breast and other cancers. While the role
of CHEK2 in cancer susceptibility has been generally well
studied, published cancer risk estimates are limited to those
conferred by the more common CHEK2 founder mutations
(Supplemental Table S1). The c.1100delC Eastern European
founder mutation is the most comprehensively studied CHEK2
mutation. Results from large case-control studies have shown
a 2-fold increased risk for breast and colorectal cancers (1,2)
with cancer risks further increased among individuals with family
histories of these cancers. After initial reports of c.1100delC’s
association with cancer, several other European founder mu-
tations have been reported including c.444 + 1G > A, p.I157T,
and EX8_9del, a ~5.5 kb deletion spanning coding exons 8
and 9 (exons 9 and 10). The c.444 + 1G > A and EX8_9del
mutations have been associated with increased breast, pros-
tate, gastric and thyroid cancer risks (3–8). The p.I157T mutation
has been associated with increased risks of breast, colon, kidney,
prostate, and thyroid cancers; however, the female breast cancer
risk of approximately 1.5-fold is attenuated compared to other
CHEK2 mutations (3,9,10). An additional founder mutation,
p.S428F, has been identified in the Ashkenazi Jewish popu-
lation and is reported to confer an approximate 2-fold increase
in breast cancer risk among female carriers (11).
In a number of CHEK2 cancer risk studies, CHEK2
genotyping was limited to one or more founder mutations for
at least part of the study cohort, and limited to the founder
ethnic group. As such, little is known about the full spectrum
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of CHEK2 mutations in cancer cohorts across diverse ethnic
groups, and cancer risk estimates for CHEK2 mutation carriers
(CHEK2 + s) of non-founder mutations remain largely unde-
fined. With the clinical availability of multi-gene panel testing
(MGPT) for hereditary cancer, an increased number of
CHEK2 + s is being reported. In multiple breast/ovarian cancer
MGPT cohort studies, CHEK2 mutations have accounted for
15–33% of non-BRCA1/2 mutations identified (12–15).
In a recent update to the National Comprehensive Cancer
Network (NCCN) Genetic/Familial High-Risk Assessment
Guideline, screening breast MRIs are recommended for
CHEK2 + s as their lifetime breast cancer risk exceeds 20%
(16). It is currently unclear whether these recommendations
are appropriate for all CHEK2 + s. In this study, we aimed to
assess the phenotypes and molecular characteristics across
a full spectrum of CHEK2 mutations from a multi-gene cancer
panel cohort, with a focus on comparing phenotypes of founder
and non-founder mutation carriers.
Methods
Study population
Clinical histories and molecular test results were reviewed for
all patients who underwent MGPT including CHEK2 between
March 2012 and June 2015, regardless of personal cancer
history (n = 45,879). The following information was ex-
tracted from test requisition forms and clinic notes submitted
by ordering providers: gender, age at testing, ethnicity, and
personal/family cancer history.
Laboratory methods
MGPT was performed as previously described (17). In
summary, genomic deoxyribonucleic acid (gDNA) was iso-
lated from whole blood or saliva samples using QIAsymphony
DNA kits (Qiagen, Valencia, CA) and then quantified using a
spectrophotometer (Nanodrop; Thermo Scientific, Pittsburgh,
PA, or Infinite F200; Tecan, San Jose, CA). Sequence en-
richment was performed (RainDance Technologies, Billerica,
MA), followed by next-generation sequence (NGS) analysis
(Illumina, San Diego, CA) of all coding domains plus at least
five bases into the 5′ and 3′ ends of all introns and untranslated
regions (5’UTR and 3′UTR) of 14–49 cancer susceptibility
genes, depending on the panel ordered. Sanger sequenc-
ing was performed for any region with insufficient depth of
coverage for reliable heterozygous variant detection (<10×)
and for verification of all variant calls other than known non-
pathogenic alterations. A targeted chromosomal microarray
designed with increased probe density in regions of interest
was used for the detection of gross deletions and duplica-
tions for each sample (Agilent, Santa Clara, CA). Initial data
processing and base calling, including extraction of cluster in-
tensities, were done using RTA 1.12.4 (HiSeq Control Software
1.4.5; Illumina). Sequence quality filtering was executed with
the CASAVA software (version 1.8.2; Illumina, Hayward, CA).
Sequence fragments were aligned to the reference human
genome (GRCh37), and variant calls were generated using
CASAVA. A minimum quality threshold of Q20 was applied,
translating to an accuracy of >99.9% for called bases. Vari-
ants were annotated with the Ambry Variant Analyzer, a
proprietary alignment and variant annotation software (Ambry
Genetics). All variants, with the exception of previously
characterized benign alterations, underwent thorough assess-
ment and review of available evidence (e.g., population
frequency information, published case reports, case/control
and functional studies, internal co-occurrence and co-
segregation data, evolutionary conservation, and in silico
predictions). Variants were further classified per Ambry’s five-
tier variant classification protocol (pathogenic mutation; variant,
likely pathogenic (VLP); variant of unknown significance (VUS);
variant, likely benign (VLB); and benign), which is based on
published recommendations/guidelines by the American College
of Medical Genetics and Genomics and the International
Agency for Research on Cancer (18,19).
Data analysis
CHEK2 pathogenic mutation and VLP carriers were further
classified as “founder mutation carriers” if they harbored the
c.1100delC, p.I157T, p.S428F, EX8_9del, or c.444 + 1G > A
pathogenic mutations or as “non-founder mutation carriers” if
they harbored any other CHEK2 alterations classified as patho-
genic or VLP (17). The overall frequencies of founder, non-
founder and all CHEK2 mutations were calculated and compared
between Caucasians and non-Caucasians. Phenotypes of
founder and non-founder mutation carriers were compared
based on personal history of any cancer, multiple primary
cancers, and history of the following cancer types: breast (any,
female, male and multiple breast primaries), colorectal, ovarian,
endometrial, thyroid, kidney, prostate, pancreatic, leukemia,
lymphoma, brain, and gastric. History of these cancer types
among first, second, or third-degree relatives was also com-
pared between the two groups. The reduced penetrance p.I157T
mutation was excluded from phenotype comparisons.
CHEK2 + s lacking clinical history information, and individu-
als harboring biallelic CHEK2 mutations or mutations in additional
cancer susceptibility genes were excluded from the analyses.
Additional personal and family history comparisons were
performed for the CHEK2 + s cohort (excluding p.I157T) vs.
MGPT negative controls (MGPT-) as a means of validating
the ability to detect significant differences within a highly
selected cancer cohort. Subsequent comparisons of p.I157T
vs. other CHEK2 + s and MGPT- were performed. Statistical
analyses were performed using the Fisher’s exact test and
multivariate logistic regression analysis adjusted for multiple
comparisons via false discovery rate (FDR cutoff of 5% applied)
estimation, controlling for age at testing, MGPT ordered, eth-
nicity, and gender. The final cohort for phenotype comparisons
consisted of 31,080 individuals.
Results
CHEK2 positive cohort
The overall frequency of CHEK2 + s in this MGPT cohort was
1085/45,879 (2.4%), including 83 individuals carrying addi-
tional mutations in non-CHEK2 genes and 16 individuals
harboring biallelic CHEK2 mutations. The majority of CHEK2 + s
were female (n = 1001, 92.3%) and Caucasian (n = 824, 75.9%).
Other ethnicities included African American (n = 8, 0.7%),
Ashkenazi Jewish (n = 120, 11.1%), Asian (n = 10, 0.9%),
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Hispanic (n = 14, 1.3%), Middle Eastern (n = 6, 0.6%), Mixed
Ethnicity (n = 31, 2.9%), “Other” (n = 6, 0.6%), and Native
American (n = 1, 0.1%). Ethnicity was not provided for 65 par-
ticipants (6.0%).
Of the 1101 CHEK2 mutations identified, 841 (76.4%) were
founder mutations, and 260 (23.6%) were non-founder mu-
tations (Table 1). The most commonly detected founder
mutations were c.1100delC (n = 416) and p.I157T (n = 258),
which represented 80.1% of the total number of founder mu-
tations observed. Founder mutations accounted for 96.7% of
Ashkenazi Jewish, 76.9% of Caucasian, 57.1% of Hispanic,
and 100% of Native American CHEK2 + s. Additionally, founder
mutations accounted for 64.5% of mixed ethnicity, 66.2% of
unknown ethnicity, and 66.7% of “other” ethnicity CHEK2 + s.
Conversely, founder mutations accounted for 37.5% of CHEK2
mutations in African Americans and were not detected among
Middle Eastern or Asian subjects.
Overall, CHEK2 mutations were significantly more fre-
quent among Ashkenazi Jews and Caucasians than non-
Caucasians/non-Ashkenazi Jews (OR = 4.63, p = 1.48e-32,
95%CI [3.36, 6.56]), with the frequency of founder muta-
tions greater between these groups as well (OR = 11.97,
p = 1.29e-40, 95%CI [6.81, 23.29]). The c.1100delC founder
mutation was more frequent among Caucasians than non-
Caucasians/non-Ashkenazi Jews (OR = 14.75, p = 5.83e-14,
95%CI [4.98, 72.11]). The p.S428F founder mutation was
more frequent among Ashkenazi Jews than non-Ashkenazi
Jews (OR = 52.16, p = 2.97e-73, 95%CI [31.60, 89.97]).
One recurrent non-founder mutation, p.H371Y, was less
frequent among Caucasians than non-Caucasians (OR = 0.00,
p = 0.003, 95%CI [0.00, 0.46]). This may represent an
Asian founder mutation since 4 of 5 carriers reported Asian
ancestry, although background haplotype analysis was not
performed.
Table 1 CHEK2 mutation spectrum
Total
Ashkenazi
Jewish Caucasian
Middle
Eastern Hispanic
African
American Asian
Native
American Other
Mixed
ethnicity Unknown
nb nc nb nc nb nc nb nc nb nb nb nb nb nb nb
Total tested – 45,879 – 3,039 – 31,196 – 262 2,129 2,335 1,630 54 162 2,016 3,056
Any CHEK2 mutation 1,101 1,085 122 120 837 824 7 6 14 8 10 1 6 31 65
CHEK2 founders 841 831 118 116 644 636 0 0 8 3 0 1 4 20 43
c.1100delC 416 412 21 21 352 348 0 0 6 3 0 1 2 14 17
p.S428F 108 108 82 82 20 20 0 0 0 0 0 0 1 1 4
EX8_9dela 30 30 1 1 25 25 0 0 0 0 0 0 0 0 4
c.444 + 1G > A 29 29 0 0 27 27 0 0 1 0 0 0 0 0 1
p.I157T 258 257 14 14 220 219 0 0 1 0 0 0 1 5 17
CHEK2 non-founders 260 259 4 4 193 193 7 6 6 5 10 0 2 11 22
Recurrent 221 220 3 3 165 165 7 6 4 4 6 0 2 11 19
p.T476M 67 66 3 3 46 46 6 5 0 0 0 0 2 3 7
p.R117G 40 40 0 0 35 35 0 0 0 1 1 0 0 0 3
c.1263delT 12 12 0 0 11 11 0 0 0 0 0 0 0 0 1
p.R145W 9 9 0 0 7 7 0 0 1 0 0 0 0 0 1
p.G167R 8 8 0 0 6 6 1 1 0 0 1 0 0 0 0
c.591delA 8 8 0 0 7 7 0 0 0 0 0 0 0 1 0
p.G306A 7 7 0 0 6 6 0 0 0 0 0 0 0 0 1
p.R95* 6 6 0 0 4 4 0 0 0 1 0 0 0 0 1
c.1368dupA 6 6 0 0 5 5 0 0 0 0 0 0 0 0 1
p.H371Y 5 5 0 0 0 0 0 0 0 0 4 0 0 1 0
p.R519* 5 5 0 0 3 3 0 0 0 0 0 0 0 2 0
EX2_3dela 5 5 0 0 4 4 0 0 0 0 0 0 0 1 0
c.1567delC 4 4 0 0 3 3 0 0 0 0 0 0 0 1 0
c.277delT 4 4 0 0 3 3 0 0 0 0 0 0 0 0 1
p.R137* 3 3 0 0 2 2 0 0 0 1 0 0 0 0 0
p.Y390S 3 3 0 0 3 3 0 0 0 0 0 0 0 0 0
p.W93* 3 3 0 0 2 2 0 0 0 0 0 0 0 1 0
c.908 + 1G > A 3 3 0 0 3 3 0 0 0 0 0 0 0 0 0
c.683 + 1G > T 3 3 0 0 2 2 0 0 0 0 0 0 0 0 1
5’UTR_EX1dela 3 3 0 0 2 2 0 0 0 1 0 0 0 0 0
c.793-1G > A 3 3 0 0 0 0 0 0 3 0 0 0 0 0 0
c.1434delA 2 2 0 0 2 2 0 0 0 0 0 0 0 0 0
c.247delC 2 2 0 0 1 1 0 0 0 0 0 0 0 1 0
EX3_4dela 2 2 0 0 1 1 0 0 0 0 0 0 0 0 1
c.1462-2A > G 2 2 0 0 2 2 0 0 0 0 0 0 0 0 0
c.319 + 2T > A 2 2 0 0 2 2 0 0 0 0 0 0 0 0 0
5′UTRdel 2 2 0 0 1 1 0 0 0 0 0 0 0 0 1
5′UTR_EX14dela 2 2 0 0 2 2 0 0 0 0 0 0 0 0 0
Non-recurrent 39 39 1 1 28 28 0 0 2 1 4 0 0 0 3
a Coding exon nomenclature.
b Number of CHEK2 mutations detected (when number of mutations and number of individuals is equal, this designation is used).
c Number of CHEK2 mutation-positive individuals (if different from number of mutations detected).
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Phenotype comparisons
When compared to MGPT-, CHEK2 + s (excluding p.I157T)
were significantly more likely to have a personal history of any
cancer, multiple primaries, female and multiple primary breast
cancers, and thyroid cancer, and were significantly less likely
to have a personal history of ovarian cancer (Table 2).
CHEK2 + s were also significantly more likely to have a family
history of female breast cancer, leukemia, thyroid and pros-
tate cancers (Table 2). No significant differences were observed
between personal and family cancer histories of founder and
non-founder CHEK2 + s (Table 2).
No significant phenotypic differences were observed
between p.I157T mutation carriers (p.I157T + s) and all other
CHEK2 + s (Supplemental Table S2). When compared to
MGPT-, the only observed difference was that p.I157T + s
were significantly more likely to have leukemia (OR = 5.85,
p = 5.94e-3, 95%CI [1.55, 15.72]; multivariate logistic regres-
sion analysis p = 0.03).
Discussion
To our knowledge, we have examined the largest CHEK2 + cohort
ascertained through comprehensive CHEK2 analysis to date.
While the majority of CHEK2 + s (76.4%) harbored founder mu-
tations with published cancer risk estimates, 23.6% of patients
harbored non-founder mutations for which cancer risk infor-
mation is undefined. No significant differences were observed
between personal and family histories of CHEK2 founder and
non-founder mutation carriers, suggesting that cancer risks re-
ported in CHEK2 founder populations may be generalizable to
all CHEK2 + s. Compared to MGPT-, CHEK2 + s were more
likely to have a personal history of breast or thyroid cancer;
Table 2 Phenotype comparisons across individuals tested for CHEK2 (excluding p.I157T carriers)
Positive Negative Founder Non-founder Positive vs. negative Founder vs. non-founder
Personal history % p-valuea OR 95% CI
Multivariate
p-valueb p-valuea OR 95% CI
Multivariate
p-valueb
Any cancer 85.0% 77.9% 85.5% 83.9% 1.97e-6 1.61 [1.31, 2.00] 8.60e-06 0.58 1.13 [0.71, 1.77] 0.99
Multiple primary
cancers
24.0% 17.8% 25.1% 21.4% 0.00 1.32 [1.10, 1.58] 3.18e-05 0.38 1.21 [0.81, 1.83] 0.84
Breast 70.3% 56.9% 69.9% 71.0% 2.20e-13 1.79 [1.52, 2.11] 5.99e-14 0.79 0.95 [0.66, 1.36] 0.99
Multiple primary
breast
12.6% 8.3% 13.6% 10.3% 0.00 1.59 [1.26, 1.99] 8.32e-05 0.23 1.37 [0.82, 2.38] 0.98
Female breast 74.9% 61.0% 74.8% 75.1% 4.16e-14 1.91 [1.60, 2.29] 1.80e-13 1.00 0.99 [0.66 1.46] 0.99
Male breast 12.7% 7.5% 12.5% 13.3% 0.19 1.80 [0.68, 4.08] 0.07 1.00 0.93 [0.13, 10.91] 0.99
Colorectal 6.7% 8.6% 7.5% 4.9% 0.07 0.76 [0.56, 1.02] 0.10 0.26 1.56 [0.76, 3.46] 0.84
Ovarian 6.0% 9.1% 6.0% 6.2% 0.01 0.64 [0.46, 0.88] 0.01 0.86 0.96 [0.47, 2.06] 0.98
Endometrial 2.5% 3.4% 2.6% 2.4% 0.24 0.73 [0.42, 1.18] 0.28 1.00 1.07 [0.35, 3.94] 0.99
Thyroid 3.7% 2.1% 3.3% 4.5% 0.01 1.77 [1.15, 2.62] 0.01 0.52 0.74 [0.31, 1.84] 0.84
Kidney 1.8% 1.0% 1.8% 1.8% 0.06 1.76 [0.92, 3.07] 0.19 1.00 0.99 [0.27, 4.46] 0.99
Prostate 10.9% 8.0% 5.0% 26.7% 0.45 1.41 [0.49, 3.35] 0.73 0.04 0.15 [0.01, 1.21] 0.74
Pancreas 1.1% 0.7% 1.0% 1.3% 0.27 1.49 [0.63, 3.01] 0.49 0.71 0.73 [0.14, 4.76] 0.99
Leukemia 0.5% 0.3% 0.6% 0.4% 0.30 1.76 [0.47, 4.69] 0.38 1.00 1.32 [0.11, 69.83] 0.99
Lymphoma 0.7% 0.8% 1.0% 0.0% 0.84 0.81 [0.26, 1.93] 0.73 0.33 Inf [0.40, Inf] 0.99
Brain 0.7% 0.4% 1.0% 0.0% 0.26 1.58 [0.50, 3.82] 0.48 0.33 Inf [0.40, Inf] 0.99
Gastric 0.5% 0.5% 0.6% 0.4% 0.78 1.12 [0.30, 2.95] 0.79 1.00 1.32 [0.11, 69.83] 0.99
Family history % p-valuea OR 95% CI
Multivariate
p-valueb p-valuea OR 95% CI
Multivariate
p-valueb
Any cancer 97.8% 97.6% 98.2% 96.8% 0.81 1.10 [0.67, 1.95] 0.76 0.27 1.82 [0.57, 5.58] 0.84
Breast 77.1% 72.3% 78.3% 74.3% 0.00 1.29 [1.08, 1.55] 0.01 0.25 1.25 [0.84, 1.84] 0.98
Multiple primary
breast
11.2% 9.1% 11.3% 11.0% 0.06 1.26 [0.98, 1.60] 0.12 1.00 1.03 [0.61, 1.79] 0.99
Female breast 76.1% 70.6% 77.5% 72.9% 0.00 1.33 [1.12, 1.59] 0.00 0.18 1.28 [0.87, 1.87] 0.84
Male breast 3.1% 2.4% 3.6% 1.8% 0.26 1.29 [0.80, 1.99] 0.33 0.25 1.98 [0.64, 8.16] 0.84
Colorectal 37.9% 34.7% 38.4% 36.7% 0.08 1.15 [0.98, 1.34] 0.13 0.74 1.07 [0.76, 1.52] 0.99
Ovarian 18.9% 22.2% 18.3% 20.2% 0.04 0.82 [0.67, 0.99] 0.07 0.60 0.88 [0.58, 1.36] 0.84
Endometrial 9.0% 10.5% 10.5% 5.5% 0.24 0.85 [0.64, 1.10] 0.30 0.03 2.02 [1.04, 4.24] 0.74
Thyroid 8.2% 5.4% 8.9% 6.4% 0.00 1.58 [1.18, 2.07] 0.00 0.30 1.43 [0.75, 2.89] 0.84
Kidney 7.5% 6.0% 7.4% 7.8% 0.10 1.27 [0.94, 1.69] 0.17 0.88 0.94 [0.50, 1.82] 0.99
Prostate 26.9% 21.8% 27.6% 25.2% 0.00 1.32 [1.11, 1.57] 0.00 0.52 1.13 [0.78, 1.66] 0.99
Pancreas 13.3% 13.5% 14.3% 11.0% 0.96 0.99 [0.78, 1.23] 0.91 0.28 1.35 [0.81, 2.31] 0.84
Leukemia 13.0% 8.6% 13.5% 11.9% 0.00 1.59 [1.26, 1.99] 0.00 0.63 1.15 [0.70, 1.95] 0.99
Lymphoma 8.7% 7.3% 9.3% 7.3% 0.15 1.22 [0.93, 1.59] 0.21 0.47 1.30 [0.70, 2.52] 0.84
Brain 12.1% 9.8% 12.3% 11.5% 0.04 1.27 [1.00, 1.60] 0.09 0.80 1.08 [0.65, 1.86] 0.99
Gastric 10.4% 11.0% 9.3% 12.8% 0.67 0.94 [0.73, 1.20] 0.76 0.18 0.70 [0.42, 1.20] 0.74
a The p-value of the Fisher’s exact test.
b The p-value of the multivariate logistic regression analysis, adjusted for multiple comparisons via false discovery rate (cutoff of 5%) estimation, controlling for age at
testing, MGPT ordered, ethnicity, and gender.
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however, no significant differences were observed for other re-
ported CHEK2-associated cancers (colorectal, prostate, and
kidney). This observation can be partially attributed to an as-
certainment bias of the MGPT cohort as the most common
indication for testing was breast cancer, with 70.3% of CHEK2 + s
and 56.9% of MGPT- reporting a personal history of breast cancer.
All other cancer types assessed were reported at relatively lower
frequencies (i.e. ≤10%) among CHEK2 + s and MGPT- pa-
tients. Future studies incorporating larger numbers of mutation
carriers with cancers other than breast are needed to further
evaluate whether risks for other cancers are similar among
founder and non-founder mutation carriers.
Several other limitations should be noted. While all patients
underwent comprehensive analysis of CHEK2, additional testing
varied. It is possible that some MGPT- harbor mutations in genes
not tested or that CHEK2 + s carry an additional non-CHEK2
mutation, although the spectrum of MGPT ordered was con-
trolled for in multivariate logistic regression analysis.Also, grouping
the founder mutations together results in over-representation
of the most common mutation in this cohort (c.1100delC) and
under-representation of the least common founder mutation
(c.444 + 1G > A). This is reasonable for estimating breast cancer
risk, as the non-p.I157T founder mutations have been asso-
ciated with an increased breast cancer risk of similar magnitude,
but could confound the analysis for other cancer types since
the various founder mutations have somewhat differing cancer
profiles. Finally, phenotype data were collected primarily from
clinician-completed requisition forms, introducing potential for
incomplete reporting of a patient’s cancer history.
Due to the previously reported lower breast cancer risk with
the p.I157T mutation relative to the other four founder muta-
tions, p.I157T + s were analyzed separately. The observation
that cancer risks among p.I157T + s were moderate, falling
between the higher risks in other CHEK2 + s and lower risks
in MGPT- suggests a gradient of risk, with p.I157T represent-
ing a lower penetrance allele, as expected.
Continued CHEK2 testing via MGPT will further our knowl-
edge of the full CHEK2 mutation spectrum and allow for additional
founder mutations to emerge among ethnic minorities with sample
sizes historically inadequate to identify obvious trends. The data
presented here supports the generalizability of cancer risks from
founder populations to carriers of other CHEK2 mutations, with
the exception of the p.I157T known reduced penetrance allele.
Additional studies are warranted to confirm precise non-breast
cancer risks, age-related penetrance and appropriate screen-
ing protocols. However, in the setting of any (non-p.I157T) clinically
identified CHEK2 mutation, patients should be targeted to updated
NCCN screening protocols. This provides an effective frame-
work for supporting NCCN recommendations for intensive breast
cancer surveillance among CHEK2 + s.
Appendix: Supplementary data
Supplementary data related to this article can be found online
at doi:10.1016/j.cancergen.2016.08.005.
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